News

Biologics to watch in 2013
Enlarge image

OutlookEUUK

Biologics to watch in 2013

02.01.2013 - At the beginning of the new year, 29 monoclonal antibody (mAbs) drugs are in Phase III clinical development.

While around 350 therapeutic mAbs are currently in clinical development globally, only 28 had entered active Phase 2/3 or Phase 3 studies as of January 2013, according to MABS. Additionally one mAb mixture was under evaluation in Phase III. Historically, mAbs that target antigens relevant to cancer have comprised approximately 50% of the mAb clinical pipeline, but in 2013 the picture has changed: 66% or 19 of the antibodies to watch in 2013 are for non-cancer indications.

The non-cancer mAbs include alirocumab (Regeneron; Sanofi, hypercholesterinemia); AMG 145 (Amgen, hypercholesterinemia), epratuzumab (UCB, SLE), gantenerumab (Roche; Alzheimer’s disease), gevokizumab (Xoma/Servier, Non-infectious uveitis), itolizumab (Biocon, Plaque psoriasis), ixekizumab (Eli Lilly and Co., psoriasis), lebrikizumab (Roche/Genentech, rheumatoid arthritis), mepolizumab (GSK, Asthma, COPD etc.), ocrelizumab (Roche/Genentech, multiple sclerosis), reslizumab (Teva, Eosinophilic asthma), romosozumab (Amgen, Postmenopausal osteoporosis), sarilumab (Regeneron; Sanofi, rheumatoid arthritis), secukinumab (Novartis, rheuma, psoriasis), sirukumab (Janssen R&D LLC, rheumatoid arthritis), solanezumab (Eli Lilly and Co., Alzheimer’s disease), tabalumab (Eli Lilly and Co., rheuma, SLE) and vedolizumab (Millenium, Ulcerative colitis; Crohn disease). The mixture of actoxumab and bezlotoxumab (MK-3415A, Merck & Co.) is being evaluated in two Phase 3 studies as a treatment for Clostridium difficile infection.  

The ten cancer mAbs are: elotuzumab (Bristol-Myers Squibb, Abbott, multiple myeloma), farletuzumab (Morphotek, ovarian cancer), inotuzumab ozogamicin (Pfizer; UCB, ALL, NHL), naptumomab estafenatox (Active Biotech, renal cell carcinoma), necitumumab (ImClone LLC, NSCL), nivolumab (Bristol-Myers Squibb, NSCL, renal cell carcinoma), obinutuzumab (Roche/Genetech, Diffuse large B cell lymphoma, CLL, NHL), onartuzumab (Roche/Genetech, NSCL cancer; gastric cancer), racotumomab (CIMAB; Laboratorio Elea S.A.C.I.F. y A, NSCL), and ramucirumab (ImClone LLC, Gastric; liver, breast, colorectal, NSCL cancers).

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/biologics-to-watch-in-2013.html

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE12.51 EUR18.92%
  • CO.DON2.88 EUR9.09%
  • FORMYCON26.77 EUR8.91%

FLOP

  • 4SC1.16 EUR-7.20%
  • MOLOGEN5.69 EUR-2.07%
  • CYTOS1.43 CHF-1.38%

TOP

  • CYTOS1.43 CHF320.6%
  • MEDIGENE12.51 EUR194.4%
  • FORMYCON26.77 EUR60.3%

FLOP

  • MORPHOSYS60.10 EUR-19.6%
  • BASILEA108.20 CHF-11.5%
  • WILEX3.10 EUR-9.6%

TOP

  • SANTHERA96.50 CHF2282.7%
  • FORMYCON26.77 EUR269.2%
  • WILEX3.10 EUR229.8%

FLOP

  • CYTOS1.43 CHF-52.3%
  • MOLOGEN5.69 EUR-49.9%
  • PAION2.53 EUR-30.3%

No liability assumed, Date: 31.03.2015